Latest News
Alkermes initiates phase 2 study of ALKS 7290 for major depressive disorder
30 October 2026 - Biopharmaceutical company Alkermes plc (Nasdaq:ALKS) announced on Friday that it has initiated a phase 2 clinical study evaluating ALKS 7290 as an adjunctive treatment for adults with major depressive disorder (MDD), expanding the d...
Perrigo to pay quarterly dividend of USD0.29 per share
30 October 2026 - Perrigo Company plc (NYSE: PRGO), a provider of consumer self-care products, announced on Thursday that its board of directors has approved a quarterly cash dividend of USD0.29 per share, or USD1.16 per share on an annualised basis....
AFT Pharmaceuticals' COMBOGESIC pain medication available to US healthcare organisations through Mark Cuban Cost Plus Marketplace
30 October 2026 - New Zealand-based pharmaceutical company AFT Pharmaceuticals announced on Thursday that COMBOGESIC (acetaminophen 325 mg/ibuprofen 97.5mg) tablets are now available for purchase in the United States by registered healthcare organisa...
Bambusa Therapeutics prices upsized initial public offering
30 October 2026 - Bambusa Therapeutics Inc (Nasdaq:BBTX), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, announced on Thursday the pricing of its ups...
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
30 October 2026 - Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), on Thursday reported encouraging preliminary clinical results for TJ101 presented at the European Society for M...